Gene therapy for colon cancer with the herpes simplex thymidine kinase gene

Journal of Surgical Oncology

Volumn 64, Issue 4, 1997, Pages 289-294

  Link Jr , Charles J ^a   Levy, John P ^a   McCann, Leisa Z ^a   Moorman, Donald W ^b  

^a Iowa Cancer Research Foundation   (United States)

^b IOWA METHODIST MEDICAL CENTER   (United States)

Author keywords

CT 26 colonic adenocarcinoma; ganciclovir; gene therapy; herpes simplex thymidine kinase gene; retrovirus; vector producer cell

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; COLON CANCER; DRUG EFFICACY; ENZYME ANALYSIS; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE;

EID: 8244225186     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199704)64:4<289::AID-JSO7>3.0.CO;2-5     Document Type: Article

References (26)

1. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-5281.
2. Moolten FL: Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit Rev Immunol 1990;10:203-233.
3. Heyman RA, Borrelli E, Lesley J, et al.: Thymidine kinase obliteration: Creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci USA 1989;86:2698-2702.
4. Ezzeddine ZD, Martuza RL, Platika D, et al.: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991;3:608-614.
5. Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;82:297-300.
6. Oldfield EH, Ram Z, Culver KW, et al.: Gene therapy for brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993;4:39-69.
7. Link CJ, Moorman D, Seregina T, et al.: A phase I trial of in vivo gene therapy with the Herpes simplex thymidine kinase/ ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 1996;7:1161-1179.
8. Short MP, Choi BC, Lee JK, et al.: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990;27:427-439.
9. Culver KW, Ram Z, Walbridge S, et al.: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-1552.
10. Caruso M, Panis Y, Gagandeep S, et al.: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993;90:7024-7028.
11. Vile RG, Hart IR: In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993;53:962-967.
12. Chen SH, Shine HD, Goodman JC, Woo SL: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994;91:3054-3057.
13. Freeman SM, Abboud CN, Whartenby KA, et al.: The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
14. Bi WL, Parysek LM, Warnick R, Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gen Ther 1993;4:725-731.
15. Link CJ, Kolb E, Muldoon R: Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer. Hybridoma 1995;14:143-147.
16. Ram Z, Culver KW, Walbridge S, et al.: Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 1993;79:400.
17. Moorman DM, Butler DA, Stanley JD, et al.: Survival and toxicity of xenogenic murine retroviral vector producer cells in liver. J Surg Oncol 1994;57:152-156.
18. Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-990.
19. Tapscott SJ, Miller AD, Olson JM, et al.: Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994;91:8185-8189.
20. Ram Z, Culver KW, Walbridge S, et al.: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993;53:83-88.
21. Chen S, Li Chen XH, Wang Y, et al.: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995;92:2577-2581.
22. Gagandeep S, Brew R, Green B, et al.: Prodrug-activated gene therapy: involvement of an immunological component in the "by-stander effect." Cancer Gene Ther 1996;3(2):83-88.
23. Smith MJ, Rousculp MD, Goldsmith KT, et al.: Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther 1994;5:29-35.
24. Tanaka T, Kanai F, Okabe S, et al.: Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996;56:1341-1345.
25. Schrewe H, Thompson J, Bona M, et al.: Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 1990;10:2738-2748.
26. Osaki T, Tanio Y, Tachibana I, et al.: Gene therapy for carcino-embryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994;54:5258-5261.